Decrease in clinical hypoglycemia in young children with type 1 diabetes treated with free-mixed aspart and detemir insulin: an open labeled randomized trial

What Was Tested

Researchers studied Insulin Aspart and Insulin Detemir in this randomized controlled trial publication.

The trial thus compares not only D vs.

NPH, but also flexible, personalized insulin preparations vs. a fixed premixed preparation.

Who Took Part

According to the abstract, 82 children were involved.

By PubMed's age tags, the people studied were young children, children and teenagers, both men and women.

This single-center, open-label, randomized trial included 82 children with T1D.

Patients stayed on ANIM for 1 yr of optimization of disease management, then were randomized to either ANIM (N = 41) or ADIM (N = 41) for another year.

How the Study Was Run

The design is described as randomized and open-label.

Random assignment meant chance, not the researchers, decided who got Insulin Aspart and who got the comparison, which limits bias.

Everyone knew when Insulin Aspart was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

What Was Measured

The subject headings attached to it are Blood Glucose, Diabetes Mellitus, Type 1, Drug Combinations, Glycated Hemoglobin, Hypoglycemia, Hypoglycemic Agents and Insulin.

The authors tagged it with the keywords aspart-detemir mixture, diabetes children and type 1 diabetes.

What This Means in Plain Language

The paper is a randomized and open-label study of Insulin Aspart and Insulin Detemir in 82 children.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2015 (Pediatric diabetes), a journal based in China.

More context: the Insulin Aspart compound page and the Insulin Detemir compound page, all human trials.